TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10589403
Drug: Miconazole 7
Normalized name: Miconazole 7
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole 7 (seven-day treatment)
Study: 8789864
Drug: Intraoperative extraconal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative extraconal bupivacaine injection
Study: 1586374
Drug: Buccal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal administration of 5 mg ISDN
Study: 1586374
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 5 mg ISDN
Study: 6086974
Drug: Cyclic alternating
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic alternating chemotherapy with a four-drug combination of COMP
Study: 6086974
Drug: Three-drug combination
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug combination of VP-16, adriamycin and ACNU (VAN)
Study: 30420184
Drug: LDS +
Normalized name: LD norgestrel
DrugBank: Norgestrel (DB09389)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDS + EZE + ALP (triple combination)
Study: 29303450
Drug: Subcutaneous preservation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous preservation of autologous bone flap
Study: 29303450
Drug: Custom synthetic
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Custom synthetic implant
Study: 20881505
Drug: Stepwise periodized
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stepwise periodized resistance exercise program with additional rotational and full-body medicine ball exercises, 3 days/week for 12 weeks (Group 2)
Study: 12091067
Drug: Ketorolac 60
Normalized name: ketorolac 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 60 mg/daily orally in three doses plus morphine escalation
Study: 12091067
Drug: Morphine only
Normalized name: Morphine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine only
Study: 12091067
Drug: Ketorolac-morphine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac-morphine group
Study: 10334415
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg twice daily for 4 weeks)
Study: 25587645
Drug: 50 mg/d
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/d lisdexamfetamine
Study: 25587645
Drug: 70 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg/d lisdexamfetamine
Study: 25587645
Drug: 30 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/d lisdexamfetamine
Study: 24101042
Drug: Conventional fractionation
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fractionation intensity‐modulated radiation therapy (CIMRT) - 76 Gy in 38 fractions at 2.0 Gy per fraction
Study: 21744190
Drug: Application of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of stickers and criteria for switch to oral antimicrobial therapy to the drug chart in the study group post-intervention
Study: 21744190
Drug: Conventional practice
Normalized name: Practical Alchemy Purify and Protect Duo KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional practice of clinical pharmacists reviewing drug charts and contacting prescribers to discuss a switch to an oral antimicrobial in the control group
Study: 23500218
Drug: Adenosine administration
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine administration
Study: 11738309
Drug: Metoprolol (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (0.1 mg/kg)
Study: 11738309
Drug: Sotalol (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol (1.0 mg/kg)
Study: 7905095
Drug: Helicobacter pylori
Normalized name: HELICOBACTER PYLORI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helicobacter pylori eradication treatment (HET)
Study: 2721334
Drug: Naltrexone 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 2.0 mg/kg
Study: 29605395
Drug: Prophylactic dextrose
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic dextrose gel (0.5 mL/kg) rubbed into the buccal mucosa
Study: 23076338
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss intervention (26-week multidisciplinary treatment programme)
Study: 20858829
Drug: Protocol C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol C (15 HU and 600 mg I/kg)
Study: 20858829
Drug: Protocol A
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol A (12 HU and 521 mg I/kg)
Study: 20858829
Drug: Protocols B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocols B and C (15 HU and 521 mg I/kg; 15 HU and 600 mg I/kg)
Study: 20858829
Drug: Protocols A
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocols A and C (12 HU and 521 mg I/kg; 15 HU and 600 mg I/kg)
Study: 18479175
Drug: Esomeprazole 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 80 mg/day
Study: 18479175
Drug: Pantoprazole 80
Normalized name: pantoprazole 80 MG in 100 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 80 mg/day
Study: 15845680
Drug: Target-Controlled Infusion
Normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target-Controlled Infusion (TCI) of Propofol
Study: 15845680
Drug: Manually Controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manually Controlled (MAN) Propofol Infusion
Study: 2239143
Drug: Controlled-release carbamazepine
Normalized name: carbamazepine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release carbamazepine (CR CBZ)
Study: 402795
Drug: Thyrotropin-Releasing Hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin-Releasing Hormone (TRH) administered orally, 20 mg three times a day for 3 weeks (double-blind study)
Study: 402795
Drug: Thyrotropin-Releasing Hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin-Releasing Hormone (TRH) administered orally, 20 mg four times a day for 2 weeks (open controlled study)
Study: 402795
Drug: Thyrotropin-Releasing Hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin-Releasing Hormone (TRH) administered orally
Study: 31026734
Drug: Number of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of public settings used for drug consumption (shooting gallery, crack house, abandoned building, public bathroom, outside)
Study: 28234790
Drug: Levosimendan 0.2 μg/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan 0.2 μg/kg/min
Study: 28234790
Drug: Dobutamine 5 μg/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine 5 μg/kg/min
Study: 15295221
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of sunflower seed oil 3 times daily
Study: 3181323
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated measles vaccine developed in chick embryo cells
Study: 3181323
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated measles vaccines developed in human diploid cells (HDC)
Study: 3181323
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated measles vaccine developed in baby calf kidney cells
Study: 436923
Drug: Practolol 4
Normalized name: (±)-practolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practolol 4 mg/kg
Study: 436923
Drug: Propranolol 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 0.2 mg/kg
Study: 31648187
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of testosterone
Study: 25466317
Drug: Protocolized sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocolized sedation plus daily interruption (DI)
Study: 25466317
Drug: Daily interruption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily interruption (DI)
Study: 18198639
Drug: Tetramethylpyrazine (TMP)
Normalized name: Tetramethylpyrazine
DrugBank: Ligustrazine (DB19074)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetramethylpyrazine (TMP) treatment for 14 days
Study: 15990619
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for ocular hypertension with NNT of 20 for average patients, NNT of 6 for those with IOP > or =26 mm Hg.
Study: 15990619
Drug: Targeting higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeting higher risk patients for treatment.
Study: 15990619
Drug: Collaborative initial
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Collaborative initial glaucoma treatment study (CIGTS) justifying primary surgery.
Study: 8903978
Drug: Topicaina spray
Normalized name: Topicaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topicaina spray (benzocaine butyl aminobenzoate, amethocaine, butacaine)
Study: 1978605
Drug: tubocurarine 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: tubocurarine 0.05 mg/kg (group 2)
Study: 1978605
Drug: vecuronium 0.006
Approvals — FDA: no, EMA: no, PMDA: no
Description: vecuronium 0.006 mg/kg (group 3)
Study: 1978605
Drug: midazolam 0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam 0.025 mg/kg (group 4)
Study: 1978605
Drug: vecuronium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: vecuronium 0.1 mg/kg (group 5)
Study: 21521283
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel (5 or 10 g/daily) plus rhGH (0, 3 or 5 μg/kg/day)
Study: 16702472
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (CEE; 0.625 mg; n=5310)
Study: 11498833
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy to the ipsilateral breast
Study: 11498833
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) after lumpectomy and radiation therapy
Study: 9515223
Drug: Cefditoren pivoxil
Normalized name: Cefditoren Pivoxil
DrugBank: Cefditoren (DB01066)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefditoren pivoxil 100 mg preprandial
Study: 9515223
Drug: Cefditoren pivoxil
Normalized name: Cefditoren Pivoxil
DrugBank: Cefditoren (DB01066)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefditoren pivoxil 200 mg preprandial
Study: 9515223
Drug: Cefditoren pivoxil
Normalized name: Cefditoren Pivoxil
DrugBank: Cefditoren (DB01066)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefditoren pivoxil 300 mg preprandial
Study: 9515223
Drug: Cefditoren pivoxil
Normalized name: Cefditoren Pivoxil
DrugBank: Cefditoren (DB01066)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefditoren pivoxil 200 mg postprandial
Study: 9515223
Drug: Cefditoren pivoxil
Normalized name: Cefditoren Pivoxil
DrugBank: Cefditoren (DB01066)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefditoren pivoxil 200 mg every 12 hours for 7 days
Study: 8427430
Drug: Metoclopramide +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide + Ibuprofen
Study: 3679703
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg elemental zinc/day
Study: 3679703
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg elemental zinc/day
Study: 3679703
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg elemental zinc/day
Study: 29429948
Drug: VR-CBT (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: VR-CBT (16 individual therapy sessions, each 1 hour long)
Study: 29429948
Drug: Waiting list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list control (treatment as usual)
Study: 27222342
Drug: Caffeine solution
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine solution during 180 min of stationary cycling
Study: 24299727
Drug: G‐CSF (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (10 μg/kg/d) intravenously for 5 consecutive days
Study: 24299727
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no G‐CSF administration)
Study: 24354675
Drug: Korean red
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean red ginseng (KRG) 500 mg, six capsules twice a day for eight weeks
Study: 24354675
Drug: Placebo, six
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, six capsules twice a day for eight weeks
Study: 20846227
Drug: Antenatal pelvic
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal pelvic floor muscle exercises (4 sessions of taught training during pregnancy and 8-12 maximal contractions twice daily at home)
Study: 2033138
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate 0.1% cream, applied once daily
Study: 2033138
Drug: Hydrocortisone 1.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 1.0% cream, applied twice daily
Study: 7012247
Drug: Single-dose ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose ampicillin (100 mg/kg)
Study: 7012247
Drug: Five-day multiple-dose
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-day multiple-dose ampicillin (100 mg/kg per 24 hr)
Study: 25395689
Drug: Intramuscular droperidol
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular droperidol (10 mg)
Study: 25395689
Drug: Intramuscular haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular haloperidol (10 mg)
Study: 22986010
Drug: Having a
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Having a full-time job and shorter abstinence time before treatment (until 7 days)
Study: 12941676
Drug: 0.25 mg/d
Normalized name: fluoride 0.25 mg/drop oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/d of micronized 17beta-estradiol (n = 83)
Study: 11899388
Drug: Docetaxel 60-100
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 60-100 mg/m2 given as a 1-hour infusion every 3 weeks
Study: 11899388
Drug: Taxanes as
Normalized name: Taxanes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxanes as a component of first-line therapy
Study: 8888110
Drug: Desipramine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (200 mg/day for 6 weeks)
Study: 1473367
Drug: Ciprofloxacin (CIP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (CIP; 200‐300 mg, i.v. b.i.d.) + vancomycin (VAN; 0.5‐1 g, i.v. b.i.d.)
Study: 1473367
Drug: Ceftazidime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (2 g, i.v. t.i.d.) + gentamicin (1 mg/kg, i.v. t.i.d.)
Study: 31630465
Drug: Bilateral ultrasound-guided
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral ultrasound-guided erector spinae plane block using 0.3 mL/kg bupivacaine 0.25% (on each side) with a maximum dose of 2 mg/kg
Study: 31630465
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received general anesthesia with bilateral sham erector spinae plane block using 0.3 mL/kg normal saline on each side
Study: 28921547
Drug: 6% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% hydrogen peroxide (HP) for 1.5 hours daily for 21 days
Study: 28921547
Drug: 10% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbamide peroxide (CP) for 4 hours daily for 21 days
Study: 25071901
Drug: rebamipide 100
Normalized name: Rebamipide 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: rebamipide 100 mg three times per day
Study: 25071901
Drug: misoprostol 200
Normalized name: MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: misoprostol 200 μg three times per day
Study: 22916885
Drug: Fermented milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented milk supplemented with Bifidobacterium lactis Bi‐07 and Lactobacillus acidophilus NCFM, and isomaltooligosaccharide, 480 g/d for 2 weeks
Study: 10543292
Drug: Inhaled Mannitol
Normalized name: mannitol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Mannitol (300 mg)
Study: 217789
Drug: Premarin Intravenous
Normalized name: Premarin Intravenous
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premarin Intravenous
Study: 31639016
Drug: Comprehensive health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive health program (medical exercise therapy and lifestyle coaching)
Study: 22516427
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy (aspirin 325 mg daily plus clopidogrel 75 mg daily)
Study: 22516427
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy (aspirin 325 mg daily plus placebo)
Study: 16304567
Drug: Vibro-ejaculation weekly
Normalized name: VIBRIO CHOLERAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibro-ejaculation weekly for 3 months (study group)
Study: 10732934
Drug: Rifampin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (600 mg/d) and pyrazinamide (20 mg/kg per day) for 2 months
Study: 10732934
Drug: Isoniazid (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid (300 mg/d) for 12 months
Study: 3881228
Drug: Diltiazem (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (60 mg, single oral dose)
Study: 27598552
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pain education, specific exercises, and graded physical activity training
Study: 24988555
Drug: Epidural injections
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injections of glucocorticoids plus lidocaine
Study: 22162540
Drug: Trimetazidine 35-mg
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine 35-mg MR tablets in fasting state
Study: 22162540
Drug: Trimetazidine 35-mg
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine 35-mg MR tablets in fed state
Study: 22162540
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation in fasting state
Study: 22162540
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation in fed state
Study: 12153550
Drug: Lisinopril (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (dosage not specified)
Study: 11468536
Drug: Tacrolimus, corticosteroids,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus, corticosteroids, and 1 g of MMF daily (MMF-1 g group, n=79)
Study: 11468536
Drug: Tacrolimus, corticosteroids,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus, corticosteroids, and 2 g of MMF daily (MMF-2 g group, n=71)
Study: 9780474
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 5 mg i.m. weekly for 24 months
Study: 3145585
Drug: Bretschneider cardioplegic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bretschneider cardioplegic HTK solution (group I)
Study: 3145585
Drug: St. Thomas
Normalized name: St. Thomas lidpod
Approvals — FDA: no, EMA: no, PMDA: no
Description: St. Thomas cardioplegic solution (group II)
Study: 23554353
Drug: Insulin stimulation
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin stimulation in BAT
Study: 10808206
Drug: Fluconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (400 mg/day p. o. or i.v.)
Study: 10808206
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (0.2 mg/kg/day i.v.)
Study: 8928757
Drug: Insulin-like growth
Normalized name: Insulin-like growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-like growth factor I (IGF-I, 10 micrograms.kg-1.h-1 sc) for 3 days
Study: 1481646
Drug: Lisuride (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisuride (1.3 mg mean daily dose, range 0.2-2.4 mg)
Study: 1481646
Drug: Bromocriptine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (15 mg mean daily dose, range 3.75-30.0 mg)
Study: 1481646
Drug: Control (levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (levodopa and anticholinergic treatment unchanged)
Study: 16371612
Drug: Midazolam 0.5
Normalized name: midazolam 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.5 mg.kg‐1 mixed with acetaminophen suspension
Study: 16371612
Drug: Acetaminophen alone
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen alone (Control)
Study: 14556543
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg per day for 8 weeks
Study: 14556543
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg per day for 8 weeks
Study: 11524467
Drug: 0.10 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.10 mg/day of 17 beta‐estradiol by skin patch
Study: 8390287
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (CI) therapy